Finanzen von Boundless Bio, Inc. (BOLD)BOLDBoundless Bio, Inc.

Evaluating the bottom line, Boundless Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -67.86%, provide a clear picture of how effectively BOLD converts its operational activities into shareholder value.

In the context of the broader market, BOLD competes directly with industry leaders such as INMB and PMVP. With a market capitalization of $64.38M, it holds a significant position in the sector. When comparing efficiency, BOLD's gross margin of N/A stands against INMB's N/A and PMVP's N/A. Such benchmarking helps identify whether Boundless Bio, Inc. is trading at a premium or discount relative to its financial performance.

Boundless Bio has shown significant losses, with net income consistently negative, peaking at -23,693,000 USD in Q2 2026. The current ratio remains strong at 9.48, indicating good short-term liquidity despite the losses.